Exposure to Risperidone Versus Other Antipsychotics and Risk of Osteoporosis-related Fractures: a Population-based Study

Overview

Journal Acta Psychiatr Scand

Specialty Psychiatry

Date 2019 Sep 24

PMID 31545521

Citations 8

Authors

E Clapham

R Boden

J Reutfors

T Svensson

D Ramcharran

H Qiu

H Kieler

S Bahmanyar

Affiliations

Soon will be listed here.

Abstract

Objective: Antipsychotics may increase serum prolactin, which has particularly been observed with risperidone. Further, hyperprolactinemia has been linked to osteoporosis-related fractures. Therefore, we investigated fracture risk in a nationwide cohort exposed to antipsychotics.

Methods: Swedish registers were used to identify adults with two consecutive dispensations of risperidone (n = 38 211), other atypical antipsychotics not including paliperidone (n = 60 691), or typical antipsychotics (n = 17 445) within three months between 2006 and 2013. An osteoporosis-related fracture was defined as a non-open hip/femur fracture in primary analyses. Cox regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).

Results: Risperidone users were on average older (mean age of 68, 44, and 63 years for risperidone, other atypical antipsychotics, and typical antipsychotics respectively). Compared with other atypical antipsychotics, there was no association between risperidone and osteoporosis-related fractures in the overall (HR = 1.04, CI: 0.91-1.19) or age-stratified analyses. A significantly increased risk of typical antipsychotics (HR = 1.24, CI: 1.07-1.45) compared with other atypical antipsychotics remained for ages >45 years.

Conclusion: Risperidone does not appear to be associated with an increased risk of osteoporosis-related fracture compared with other atypical antipsychotic agents as a group. For typical antipsychotics, a moderately elevated risk of hip fractures was noted compared with other atypical antipsychotics, possibly because of residual confounding.

Citing Articles

Case-based Insights into Managing Co-existing Rheumatoid Arthritis and Schizophrenia.

Singh K, Panda U, Pattnaik J, Padhan P, Ravan J Indian J Psychol Med. 2024; :02537176241226928.

PMID: 39564344 PMC: 11572646. DOI: 10.1177/02537176241226928.

Risperidone accelerates bone loss in mice models of schizophrenia by inhibiting osteoblast autophagy.

Yang Z, Li P, Fan H, Pang L, Xia G, Duan C Heliyon. 2024; 10(21):e38559.

PMID: 39524718 PMC: 11550064. DOI: 10.1016/j.heliyon.2024.e38559.

Transcriptome analysis to explore the mechanism of downregulated TNIK influencing the effect of risperidone.

Yuan R, Li Y, Li X, Fu Y, Ning A, Wang D Front Pharmacol. 2024; 15:1431923.

PMID: 39268461 PMC: 11391209. DOI: 10.3389/fphar.2024.1431923.

Investigating the causal relationship between thyroid dysfunction diseases and osteoporosis: a two-sample Mendelian randomization analysis.

Qi W, Wang D, Hong Y, Yao J, Wang H, Zhu L Sci Rep. 2024; 14(1):12784.

PMID: 38834708 PMC: 11150446. DOI: 10.1038/s41598-024-62854-x.

Integration of bioinformatics and machine learning approaches for the validation of pyrimidine metabolism-related genes and their implications in immunotherapy for osteoporosis.

Feng Z, Wu Z, Zhang Y BMC Musculoskelet Disord. 2024; 25(1):402.

PMID: 38778304 PMC: 11110368. DOI: 10.1186/s12891-024-07512-z.

References

Lee S, Hsu W, Lai C, Esmaily-Fard A, Tsai Y, Chiu C . Use of antipsychotics increases the risk of fracture: a systematic review and meta-analysis. Osteoporos Int. 2017; 28(4):1167-1178. DOI: 10.1007/s00198-016-3881-3. View

Sorensen H, Jensen S, Nielsen J . Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis. Eur Neuropsychopharmacol. 2013; 23(8):872-8. DOI: 10.1016/j.euroneuro.2013.04.002. View

Brannstrom J, Lovheim H, Gustafson Y, Nordstrom P . Association Between Antidepressant Drug Use and Hip Fracture in Older People Before and After Treatment Initiation. JAMA Psychiatry. 2019; 76(2):172-179. PMC: 6440395. DOI: 10.1001/jamapsychiatry.2018.3679. View

Vancampfort D, Firth J, Schuch F, Rosenbaum S, Mugisha J, Hallgren M . Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry. 2017; 16(3):308-315. PMC: 5608847. DOI: 10.1002/wps.20458. View

Nilsson L, Petersson C . [Consumption of psychopharmaceuticals in residential facilities for the elderly. Evaluation of the extent, indications and effects]. Lakartidningen. 2001; 98(12):1371-3. View

Clapham E, Boden R, Reutfors J, Svensson T, Ramcharran D, Qiu H . Exposure to risperidone versus other antipsychotics and risk of osteoporosis-related fractures: a population-based study. Acta Psychiatr Scand. 2019; 141(1):74-83. PMC: 6973241. DOI: 10.1111/acps.13101. View

Halbreich U, Kinon B, Gilmore J, Kahn L . Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2002; 28 Suppl 1:53-67. DOI: 10.1016/s0306-4530(02)00112-9. View

De Hert M, Detraux J, Stubbs B . Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review. Expert Opin Drug Saf. 2016; 15(6):809-23. DOI: 10.1517/14740338.2016.1167873. View

Nieves J, Bilezikian J, Lane J, Einhorn T, Wang Y, Steinbuch M . Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int. 2009; 21(3):399-408. DOI: 10.1007/s00198-009-0962-6. View

10.

OKeane V . Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008; 22(2 Suppl):70-5. DOI: 10.1177/0269881107088439. View

11.

Wu H, Deng L, Zhao L, Zhao J, Li L, Chen J . Osteoporosis associated with antipsychotic treatment in schizophrenia. Int J Endocrinol. 2013; 2013:167138. PMC: 3652172. DOI: 10.1155/2013/167138. View

12.

Fraser L, Liu K, Naylor K, Hwang Y, Dixon S, Shariff S . Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. JAMA Intern Med. 2015; 175(3):450-2. DOI: 10.1001/jamainternmed.2014.6930. View

13.

Cather C, Pachas G, Cieslak K, Evins A . Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations. CNS Drugs. 2017; 31(6):471-481. PMC: 5646360. DOI: 10.1007/s40263-017-0438-8. View

14.

Bostwick J, Guthrie S, Ellingrod V . Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2008; 29(1):64-73. DOI: 10.1592/phco.29.1.64. View

15.

Wettermark B, Hammar N, Fored C, MichaelFored C, Leimanis A, Olausson P . The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2006; 16(7):726-35. DOI: 10.1002/pds.1294. View

16.

Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B . Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry. 2004; 65(11):1491-8. DOI: 10.4088/jcp.v65n1108. View

17.

Torstensson M, Leth-Moller K, Andersson C, Torp-Pedersen C, Gislason G, Holm E . Danish register-based study on the association between specific antipsychotic drugs and fractures in elderly individuals. Age Ageing. 2016; 46(2):258-264. DOI: 10.1093/ageing/afw209. View

18.

Ludvigsson J, Otterblad-Olausson P, Pettersson B, Ekbom A . The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009; 24(11):659-67. PMC: 2773709. DOI: 10.1007/s10654-009-9350-y. View

19.

Mattsson B, Rutqvist L . Some aspects on validity of breast cancer, pancreatic cancer and lung cancer registration in Swedish official statistics. Radiother Oncol. 1985; 4(1):63-70. DOI: 10.1016/s0167-8140(85)80063-3. View

20.

Pisani P, Renna M, Conversano F, Casciaro E, Di Paola M, Quarta E . Major osteoporotic fragility fractures: Risk factor updates and societal impact. World J Orthop. 2016; 7(3):171-81. PMC: 4794536. DOI: 10.5312/wjo.v7.i3.171. View